[ERCC1 mRNA expression levels and outcome of gastric cancer patients receiving oxaliplatin-based chemotherapy].
Wei
Jia
J
Zou
Zheng-yun
ZY
Qian
Xiao-ping
XP
Wang
Li-feng
LF
Yu
Li-xia
LX
Liu
Bao-rui
BR
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D004359:Drug Therapy, Combination; D004720:Endonucleases / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D000077150:Oxaliplatin; D012333:RNA, Messenger / Q000187:drug effects* / Q000378:metabolism; D013223:Statistics as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D000077150:Oxaliplatin; C071447:ERCC1 protein, human; D004720:Endonucleases; D005472:Fluorouracil